Stay updated on A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Sign up to get notified when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.

Latest updates to the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference1.0%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check72 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check86 days agoChange DetectedThe webpage has been updated to include new details about the study on Nivolumab for Hodgkin Lymphoma, specifically outlining the inclusion criteria for two cohorts of patients based on age and disease stage. Additionally, the revision version has been updated to v2.15.0.SummaryDifference41%
Stay in the know with updates to A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.